nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience
|
Eikelboom, John |
|
2016 |
129 |
11S |
p. S33-S40 8 p. |
artikel |
2 |
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures
|
Levy, Jerrold H. |
|
2016 |
129 |
11S |
p. S47-S53 7 p. |
artikel |
3 |
Evidence Supporting Idarucizumab for the Reversal of Dabigatran
|
Pollack Jr., Charles V. |
|
2016 |
129 |
11S |
p. S73-S79 7 p. |
artikel |
4 |
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols
|
Huisman, Menno V. |
|
2016 |
129 |
11S |
p. S89-S96 8 p. |
artikel |
5 |
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects
|
Reilly, Paul A. |
|
2016 |
129 |
11S |
p. S64-S72 9 p. |
artikel |
6 |
Introduction to Direct Oral Anticoagulants and Rationale for Specific Reversal Agents
|
Pollack Jr., Charles V. |
|
2016 |
129 |
11S |
p. S31-S32 2 p. |
artikel |
7 |
Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents
|
Milling Jr., Truman J. |
|
2016 |
129 |
11S |
p. S80-S88 9 p. |
artikel |
8 |
Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed
|
Milling Jr., Truman J. |
|
2016 |
129 |
11S |
p. S54-S63 10 p. |
artikel |
9 |
Safety of Direct Oral Anticoagulants: Insights from Postmarketing Studies
|
Villines, Todd C. |
|
2016 |
129 |
11S |
p. S41-S46 6 p. |
artikel |
10 |
Table of Contents
|
|
|
2016 |
129 |
11S |
p. A3-A4 nvt p. |
artikel |
11 |
Title Page
|
|
|
2016 |
129 |
11S |
p. A1- 1 p. |
artikel |